MedPath
HSA Approval

AXCEL EVILINE FORTE SUSPENSION

SIN06400P

AXCEL EVILINE FORTE SUSPENSION

AXCEL EVILINE FORTE SUSPENSION

July 4, 1991

KOTRA PHARMA MARKETING

KOTRA PHARMA MARKETING

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantKOTRA PHARMA MARKETING
Licence HolderKOTRA PHARMA MARKETING

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
General Sale List
HSA Singapore Classification

Formulation Information

SUSPENSION

ORAL

Medical Information

A02AF02

ordinary salt combinations and antiflatulents

Manufacturer Information

KOTRA PHARMA MARKETING

KOTRA PHARMA (M) SDN BHD

Active Ingredients

SIMETHICONE

40 mg/5 ml

Simethicone

ALUMINIUM HYDROXIDE (DRIED GEL)

400 mg/5 ml

Aluminum hydroxide

MAGNESIUM HYDROXIDE

400 mg/5 ml

Magnesium hydroxide

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

AXCEL EVILINE FORTE SUSPENSION - HSA Approval | MedPath